Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 1 country.
Rui MedeirosMolecular Oncology and Viral Pathology GRP-IC, Portuguese Institute of Oncology of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.ORCID 0000-0003-3010-8373
Bruno HortaMolecular Oncology and Viral Pathology GRP-IC, Portuguese Institute of Oncology of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.ORCID 0000-0003-2769-8958
Joana Freitas-SilvaCIIMAR/CIMAR, Interdisciplinary Centre of Marine and Environmental Research, Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, 4450-208 Matosinhos, Portugal.ORCID 0000-0002-0235-4991
Jani SilvaMolecular Oncology and Viral Pathology GRP-IC, Portuguese Institute of Oncology of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Francisca DiasMolecular Oncology and Viral Pathology GRP-IC, Portuguese Institute of Oncology of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.ORCID 0000-0002-4993-4467
Emília SousaCIIMAR/CIMAR, Interdisciplinary Centre of Marine and Environmental Research, Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, 4450-208 Matosinhos, Portugal.ORCID 0000-0002-5397-4672
Madalena PintoCIIMAR/CIMAR, Interdisciplinary Centre of Marine and Environmental Research, Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, 4450-208 Matosinhos, Portugal.ORCID 0000-0002-4676-1409
Fátima CerqueiraMolecular Oncology and Viral Pathology GRP-IC, Portuguese Institute of Oncology of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Universidade do Porto · PTFernando Pessoa University · PTInstituto Português de Oncologia Francisco Gentil · PT
Funding
Fundação para a Ciência e a Tecnologia POCI-01-0145-FEDER-016790; Project 3599Fundação para a Ciência e a Tecnologia UID/Multi/04546/2019Fundação para a Ciência e a Tecnologia UIDP/04423/2020
6 · The paper itself
Abstract
Xanthone derivatives have shown promising antitumor properties, and 1-carbaldehyde-3,4-dimethoxyxanthone (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effect of 1-Carbaldehyde-3,4-dimethoxyxanthone on Prostate and HPV-18 Positive Cervical Cancer Cell Lines and on Human THP-1 Macrophages. · full record | OpenQuestion